Mitoxantrone: a hypomethylating agent?

Same author

Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS.

Blood neoplasia·2026

Same author

EZH2 and intracellular Ca2+ signals interdependently coordinate alloreactive and CAR-T-cell responses.

Cellular & molecular immunology·2026

Same author

Modeling age-related methylation changes in vitro with intestinal organoids.

BMC biology·2026

Same author

DNA Methylation, Aging, and Cancer.

Epigenomes·2025

Same author

A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML.

Blood neoplasia·2025

Same author

ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer.

Cancer research·2025

Same journal

Effective treatment of human breast tumors by chimeric CCL2 and CCL8 diphtheria toxin cytotoxic peptides.

Cancer biology & therapy·2026

Same journal

NSUN2 mediates SALL2 m5C methylation to inhibit ferroptosis and promote breast cancer progression.

Cancer biology & therapy·2026

Same journal

Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.

Cancer biology & therapy·2026

Same journal

ABHD17C regulates the efficacy of lenvatinib in suppressing hepatocellular carcinoma.

Cancer biology & therapy·2026

Same journal

Advances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles.

Cancer biology & therapy·2026

Same journal

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.

Cancer biology & therapy·2026

Related Experiment Videos

Mitoxantrone: a hypomethylating agent?

Related Concept Videos

Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS.

EZH2 and intracellular Ca<sup>2+</sup> signals interdependently coordinate alloreactive and CAR-T-cell responses.

Modeling age-related methylation changes in vitro with intestinal organoids.

DNA Methylation, Aging, and Cancer.

A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML.

ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer.

Effective treatment of human breast tumors by chimeric CCL2 and CCL8 diphtheria toxin cytotoxic peptides.

<i>NSUN2</i> mediates <i>SALL2</i> m5C methylation to inhibit ferroptosis and promote breast cancer progression.

Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.

ABHD17C regulates the efficacy of lenvatinib in suppressing hepatocellular carcinoma.

Advances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles.

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude <i>versus</i> low-altitude regions: a multi-center retrospective study.

Related Experiment Videos

Mitoxantrone: a hypomethylating agent?

Related Concept Videos

Related Articles

Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS.

EZH2 and intracellular Ca<sup>2+</sup> signals interdependently coordinate alloreactive and CAR-T-cell responses.

Modeling age-related methylation changes in vitro with intestinal organoids.

DNA Methylation, Aging, and Cancer.

A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML.

ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer.

Effective treatment of human breast tumors by chimeric CCL2 and CCL8 diphtheria toxin cytotoxic peptides.

<i>NSUN2</i> mediates <i>SALL2</i> m5C methylation to inhibit ferroptosis and promote breast cancer progression.

Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.

ABHD17C regulates the efficacy of lenvatinib in suppressing hepatocellular carcinoma.

Advances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles.

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude <i>versus</i> low-altitude regions: a multi-center retrospective study.